Skip to main content
Clinical Trials/NCT02136498
NCT02136498
Completed
Not Applicable

Internet-based Medication Adherence Program for Nicotine Dependence Treatment

Kaiser Permanente1 site in 1 country66 target enrollmentOctober 2014

Overview

Phase
Not Applicable
Intervention
Varenicline
Conditions
Smoking Cessation
Sponsor
Kaiser Permanente
Enrollment
66
Locations
1
Primary Endpoint
Point Prevalence Abstinence
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

The purpose of this pilot study is to evaluate the acceptability and feasibility of the proposed smoking cessation intervention (called MyMAP or My Mobile Advice Program).

Detailed Description

Investigators will develop and pilot test a prototype of the MyMAP intervention.The intervention is designed to help smokers better manage issues known to reduce treatment adherence (withdrawal symptoms, medication side-effects, low motivation, and inadequate behavioral skills for medication adherence) and to facilitate greater communication between patients and providers so clinicians can provide appropriate oversight of medication use, intervene when medically necessary, and address patient concerns that may otherwise lead to non-adherence or early treatment termination.

Registry
clinicaltrials.gov
Start Date
October 2014
End Date
February 2016
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • An invited member of Group Health, a health care system in the Pacific Northwest
  • Plan to remain enrolled in Group Health for the next 6 months
  • aged 18 - 65
  • Eligible for smoking cessation treatment through Group Health insurance coverage
  • smoke \>= 10 cigs a day
  • speak and read in English
  • willing to use varenicline and no contraindications for this medication
  • ready to quit smoking
  • have a smart phone with internet access
  • willing to receive study texts and emails

Exclusion Criteria

  • lifetime history of dementia
  • psychosis or bipolar disorder based on self-report or medical record review
  • hearing, comprehension or visual limitations that preclude full study participation
  • current use of other forms of tobacco
  • any medical contraindication for varenicline use
  • documented history of suicidal ideation/intent

Arms & Interventions

mHealth self-help + varenicline

Participants in this control arm received standard cognitive-behavioral self-help materials delivered via a mobile health (mHealth) program + a standard course of varenicline.

Intervention: Varenicline

mHealth self-help + varenicline

Participants in this control arm received standard cognitive-behavioral self-help materials delivered via a mobile health (mHealth) program + a standard course of varenicline.

Intervention: Cognitive-behavioral self-help

mHealth MyMAP program + varenicline

Participants in the experimental arm received standard cognitive-behavioral self-help materials delivered via a mHealth program + additional personalized support features (automated, tailored advice managing nicotine withdrawal symptoms and medication side-effects \& secure messaging with a cessation counselor; i.e., MyMAP program) + a standard course of varenicline.

Intervention: Varenicline

mHealth MyMAP program + varenicline

Participants in the experimental arm received standard cognitive-behavioral self-help materials delivered via a mHealth program + additional personalized support features (automated, tailored advice managing nicotine withdrawal symptoms and medication side-effects \& secure messaging with a cessation counselor; i.e., MyMAP program) + a standard course of varenicline.

Intervention: Cognitive-behavioral self-help

mHealth MyMAP program + varenicline

Participants in the experimental arm received standard cognitive-behavioral self-help materials delivered via a mHealth program + additional personalized support features (automated, tailored advice managing nicotine withdrawal symptoms and medication side-effects \& secure messaging with a cessation counselor; i.e., MyMAP program) + a standard course of varenicline.

Intervention: MyMAP (My Mobile Advice Program)

Outcomes

Primary Outcomes

Point Prevalence Abstinence

Time Frame: 5 month follow-up

Self-report of no-smoking, even a puff during the last 7 days.

Secondary Outcomes

  • Number of Days of Varenicline Use(5 mo follow-up)

Study Sites (1)

Loading locations...

Similar Trials